Procept (PRCT): 50% rise on high volume. Why? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Procept (PRCT): 50% rise on high volume. Why?

PRCT 30.75

-1.8%

Nov 12 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ron Wargo who wrote (63)	4/2/1997 9:51:00 PM
From: Douglas	of 455

10-K is now available from Securities & Exchange Commission. I obtained an electronic version. Page 6 mentions the PRO 2000 Systemic Study. It says "In September 196, the Company began a Phase I/II study in Brussels, Belgium to evaluate PRO 2000 as an injectable drug to treat HIV positive patients. In this study, eight patients were administered drug intravenously. Although no side-effects were observed, the Company has decided to postpone, indefinitely, the development of this formulation and to concentrate all of its efforts on the clinical development of PRO 2000 as a topical microbicide. This decision was made based on several factors, including: 1) the rapid progress to date in the development of PRO 2000 as a topical microbicide, 2) the ability to clearly differentiate PRO 2000 gel as a leading drug candidate, 3)the rapidly changing competitive environment for systemic drugs to treat AIDS, and 4) a mandate to focus its efforts on its highest priority drug discovery programs." I think the survival of this Company depends on the GEL! The GEL patent is a positive, but cash is becoming critical.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next